Edgar Gerardo Dorsey-Treviño

Edgar Gerardo Dorsey-Treviño

Auto-generated profile, based on publicly available information

Edgar Gerardo Dorsey-Treviño

Department of Medicine, School of Medicine The University of Texas Rio Grande Valley Edinburg Texas USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2019 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EDE. G. Dorsey-Treviño
E. G. Dorsey-Treviño
JGJ. G. González-González
J. G. González-González
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
VGV. González-Nava
V. González-Nava
BCB. M. Contreras-Garza
B. M. Contreras-Garza
RRR. Rodriguez-Gutierrez
R. Rodriguez-Gutierrez

26 September 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
JZJorge Alberto Zuñiga-Hernandez
Jorge Alberto Zuñiga-Hernandez
EDEdgar Gerardo Dorsey-Treviño
Edgar Gerardo Dorsey-Treviño
JGJose Gerardo González-González
Jose Gerardo González-González
JBJuan P. Brito
Juan P. Brito
VMVictor M. Montori
Victor M. Montori
RRRene Rodriguez-Gutierrez
Rene Rodriguez-Gutierrez
Objectives To improve the trustworthiness of evidence, studies should be prospectively registered and research reports should adhere to existing standards. We aimed to systematically assess the degree to which endocrinology and internal medicine journals endorse study registration and reporting standards for randomised controlled trials (RCTs), systematic reviews (SRs) and observational studies (ObS). Additionally, we evaluated characteristics that predict endorsement of reporting or registration mechanism by these journals. Design Meta-epidemiological study. Setting Journals included in the ‘Endocrinology and Metabolism’ and ‘General and Internal Medicine’ 2017 Journal Citation Reports. Participants Journals with an impact factor of ≥1.0, focused on clinical medicine, and those who publish RCTs, SRs and ObS were included. Primary outcomes Requirement of adherence to reporting guideline and study registration as determined from the journals’ author instructions. Results Of the 170 (82 endocrinology and 88 internal medicine) eligible journals, endorsing of reporting standards was the highest for RCTs, with 35 (43%) of endocrine journals and 55 (63%) of internal medicine journals followed by SRs, with 21 (26%) and 48 (55%), respectively, and lastly, by ObS with 41 (50%) of endocrine journals and 21 (24%) of internal medicine journals. In 78 (46%) journals RCTs were required to be registered and published in adherence to the Consolidated Standards of Reporting Trials statement. Only 11 (6%) journals required registration of SRs. Internal medicine journals were more likely to endorse reporting guidelines than endocrine journals except for Strengthening the Reporting of Observational Studies in Epidemiology. No other journal characteristic proved to be an independent predictor of reporting standard endorsement for RCTs besides trial registration. Conclusion Our results highlight that study registration requirement and reporting guideline endorsement are suboptimal in internal medicine and endocrine journals. This malpractice may be further enhanced since endorsement does not imply enforcement, impairing the practice of evidence-based medicine.

1 December 2018 in Burns
Verified
Journal Article
Closed access
GMGabriel Ángel Mecott-Rivera
Gabriel Ángel Mecott-Rivera
JAJorge Alejandro Aguilar-Baqueiro
Jorge Alejandro Aguilar-Baqueiro
SBStephano Bracho
Stephano Bracho
IMIvette Miranda-Maldonado
Ivette Miranda-Maldonado
RFRodolfo Franco-Marquez.
Rodolfo Franco-Marquez.
MGMauricio Manuel García-Pérez
Mauricio Manuel García-Pérez

20 June 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
EDEdgar G Dorsey-Trevino
Edgar G Dorsey-Trevino
VKVarinderpal Kaur
Varinderpal Kaur
JMJosep M Mercader
Josep M Mercader
JFJose C Florez
Jose C Florez
ALAaron Leong
Aaron Leong
Context Polymorphisms in the gene encoding the glucagon-like peptide-1 receptor (GLP1R) are associated with type 2 diabetes but their effects on incretin levels remain unclear. Objective We evaluated the physiologic and hormonal effects of GLP1R genotypes before and after interventions that influence glucose physiology. Design Pharmacogenetic study conducted at 3 academic centers in Boston, Massachusetts. Participants A total of 868 antidiabetic drug-naïve participants with type 2 diabetes or at risk for developing diabetes. Interventions We analyzed 5 variants within GLP1R (rs761387, rs10305423, rs10305441, rs742762, and rs10305492) and recorded biochemical data during a 5-mg glipizide challenge and a 75-g oral glucose tolerance test (OGTT) following 4 doses of metformin 500 mg over 2 days. Main Outcomes We used an additive mixed-effects model to evaluate the association of these variants with glucose, insulin, and incretin levels over multiple timepoints during the OGTT. Results During the OGTT, the G-risk allele at rs761387 was associated with higher total GLP-1 (2.61 pmol/L; 95% CI, 1.0.72-4.50), active GLP-1 (2.61 pmol/L; 95% CI, 0.04-5.18), and a trend toward higher glucose (3.63; 95% CI, -0.16 to 7.42 mg/dL) per allele but was not associated with insulin. During the glipizide challenge, the G allele was associated with higher insulin levels per allele (2.01 IU/mL; 95% CI, 0.26-3.76). The other variants were not associated with any of the outcomes tested. Conclusions GLP1R variation is associated with differences in GLP-1 levels following an OGTT load despite no differences in insulin levels, highlighting altered incretin signaling as a potential mechanism by which GLP1R variation affects T2D risk.

19 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JGJosé Gerardo González-González
José Gerardo González-González
EDEdgar Gerardo Dorsey-Treviño
Edgar Gerardo Dorsey-Treviño
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
FBFrancisco Jesús Barrera-Flores
Francisco Jesús Barrera-Flores
AGAlejandro Díaz González-Colmenero
Alejandro Díaz González-Colmenero
RRRene Rodriguez-Gutierrez
Rene Rodriguez-Gutierrez
Trustworthy (i.e. low risk of bias) randomized clinical trials (RCTs) play an important role in evidence-based decision making. We aimed to systematically assess the risk of bias of trials published in high-impact endocrinology journals. We searched the MEDLINE/PubMed database between 2014 and 2016 for phase 2–4 RCTs evaluating endocrine-related therapies. Reviewers working independently and in duplicate used the Cochrane Risk of Bias Tool (CCRBT) to determine the extent to which the methods reported protected the results of each RCT from bias. We assessed 292 eligible RCTs, of which 40% (116) were judged to be at low risk, 43% (126) at moderate, and 17% (50) at high risk of bias. Blinding of outcome assessment was the least common domain reported 43% (125), while selective reporting of outcomes was the most common 97% (282). In multivariable analysis, RCTs with a parallel design (OR 2.4; 95% CI; 1.2–4.6) and funded by for-profit sources (OR 2.2; 95% CI; 1.3–3.6) were more likely to be at low risk of bias. Trustworthy evidence should ultimately shape care to improve the likelihood of desirable patient outcomes. Six out-of 10 RCTs published in top endocrine journals are at moderate/high-risk of bias. Improving this should be a priority in endocrine research.

21 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OCOlga G. Cantu-Rodriguez
Olga G. Cantu-Rodriguez
JHJose A. Hawing-Zarate
Jose A. Hawing-Zarate
EDEdgar G. Dorsey-Trevino
Edgar G. Dorsey-Trevino
DHDavid Hernandez-Barajas
David Hernandez-Barajas
LVLeonel E. Villalobos-Gutierrez
Leonel E. Villalobos-Gutierrez
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
Background: The lactate/pyruvate (LP) ratio has been studied as an alternative to serum lactate to determine clinical prognosis. Despite its clinical utility, there is a paucity of evidence evaluating the role of the L/P ratio in patients with sepsis. Methods: We assessed the clinical utility of the L/P ratio in patients with sepsis. The L/P ratio was measured at baseline, 4 and 8 h after admission. Our primary outcome was to determine the prognostic utility of the L/P ratio on the 15-day mortality risk. Our secondary outcomes were to compare the L/P ratio across time and its prognostic utility against standard risk calculators such as APACHE-II and SOFA scores. Results: We had a total of 80 patients, with 18 (22.5%) survivors and 62 (77.5%) non-survivors. While we found that patients having higher L/P ratios at 8 h had an increased 30-mortality risk (OR 1.08, 95% CI 1.02–1.18), the model’s performance showed no difference when compared to other measurements of the L/P ratio that showed no association with mortality (p-value: 0.45). For our secondary outcome, we found that the APACHE-II and SOFA scores have better performance and predictability than the L/P ratio (AUC 0.83 and AUC 0.80, respectively), but showed no association with mortality (OR 1.07, 95% CI 1.01–1.17 and OR 1.08, 95% CI 1.02–1.18). Conclusions: Based on our findings, the L/P ratio appears to function more effectively as an early predictor of mortality when used as an adjuvant biomarker with other clinical parameters.